Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus SAVAYSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus SAVAYSA.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs SAVAYSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inhibition of coagulation factors, primarily thrombin (factor IIa) and factor Xa, thereby preventing clot formation and propagation.
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
Intravenous: Initial bolus of 80 units/kg, followed by continuous infusion at 18 units/kg/hour. Titrate to achieve aPTT of 1.5-2.5 times control or anti-Xa level of 0.3-0.7 units/mL.
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
None Documented
None Documented
1-2 hours (dose-dependent); extends to 2.5-4 hours with continuous infusion or renal impairment; clinical context: monitoring via aPTT required
Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces.
Category A/B
Category C
Anticoagulant
Anticoagulant, Direct Factor Xa Inhibitor